MedTrace Logo

Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

NCT05238220 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 37

Last updated 2024-11-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.

Conditions

  • Kidney Transplant; Complications

Interventions

DRUG

Valganciclovir

continuation of valganciclovir prophylaxis up to 12 months with absence of demonstrated anti-CMV immunity

Sponsors & Collaborators

  • ViraCor Laboratories

    collaborator INDUSTRY

  • Piedmont Healthcare

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238220 on ClinicalTrials.gov